Zydus Lifesciences Ltd.
•₹ 1,1201.11%
2026-08-21
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Pharmaceuticals: 82.6% • Consumer Products: 14.6% • Medical Technologies: 2.9%
PROS
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.5%
- Company has a healthy return on capital (ROCE) of 23.3%
- Company comfortably covers its interest (10.1x coverage)
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
- Attractively priced for its growth - PEG of 0.8
CONS
- A large part of profit comes from other income (66.1% of PBT)
- Recent results are weak - TTM profit is down 27.2% versus prior year
- Receivables are growing faster than sales - a possible quality concern
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.58x)
- Working capital days have increased from 180 to 337 days
- Operating margins have contracted to 23.4% from 34.4%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1901.00 | 37.71 | 456113.58 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8587.00 | 77.93 | 227957.87 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 4994.90 | 87.11 | 189989.94 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1437.65 | 34.46 | 116141.01 | 0.90 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1108.80 | 24.51 | 110603.22 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2203.10 | 18.22 | 100733.42 | 0.82 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | DRREDDY | 1181.35 | 30.60 | 98604.43 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 8. | MANKIND | 2385.00 | 48.22 | 98499.54 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 9. | LAURUSLABS | 1823.00 | 90.09 | 98498.92 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1606.40 | 24.90 | 92428.71 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 412.10 | 135.59 | 67159.70 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | GLENMARK | 2325.00 | 36.50 | 65617.24 | 0.11 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
Detailed Comparison with:
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,870 | 2,050 | 2,225 | 3,173 | 4,035 | 2,512 | 2,409 | 5,634 | 2,496 | 2,809 | 2,207 | 3,565 | 2,872 | |
| 1,815 | 1,597 | 1,672 | 1,771 | 1,787 | 1,733 | 1,867 | 2,047 | 2,003 | 2,115 | 2,085 | 2,400 | 2,540 | |
| Operating Profit | — | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Income | 82 | 621 | 107 | 369 | 107 | 381 | 78 | 185 | 157 | 937 | 474 | 1,143 | 124 |
| Interest | 90 | 91 | 104 | 106 | 115 | 96 | 97 | 155 | 138 | 114 | 116 | 116 | 103 |
| Depreciation | 121 | 125 | 128 | 131 | 131 | 134 | 132 | 128 | 130 | 136 | 144 | 151 | 152 |
| 1,012 | 968 | 574 | 1,685 | 2,234 | 1,039 | 497 | 3,675 | 475 | 1,444 | 352 | 2,111 | 456 | |
| Tax % | 22.87% | 16.85% | 21.57% | 16.60% | 23.85% | 24.01% | 5.35% | 23.43% | 18.99% | 19.88% | 15.86% | 18.43% | 25.48% |
| Net Profit | 781 | 805 | 450 | 1,405 | 1,701 | 790 | 471 | 2,814 | 385 | 1,157 | 296 | 1,722 | 340 |
| 8 | 8 | 4 | 14 | 17 | 8 | 5 | 28 | 4 | 11 | 3 | 17 | 0 | |
| Equity Capital | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 100 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Equity Capital | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 101 | 100 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Jun 2023
- 2,870
- 1,815
- Operating Profit
- —
- OPM %
- —
- Other Income
- 82
- Interest
- 90
- Depreciation
- 121
- 1,012
- Tax %
- 22.87%
- Net Profit
- 781
- 8
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2023
- 2,050
- 1,597
- Operating Profit
- —
- OPM %
- —
- Other Income
- 621
- Interest
- 91
- Depreciation
- 125
- 968
- Tax %
- 16.85%
- Net Profit
- 805
- 8
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2023
- 2,225
- 1,672
- Operating Profit
- —
- OPM %
- —
- Other Income
- 107
- Interest
- 104
- Depreciation
- 128
- 574
- Tax %
- 21.57%
- Net Profit
- 450
- 4
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2024
- 3,173
- 1,771
- Operating Profit
- —
- OPM %
- —
- Other Income
- 369
- Interest
- 106
- Depreciation
- 131
- 1,685
- Tax %
- 16.60%
- Net Profit
- 1,405
- 14
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2024
- 4,035
- 1,787
- Operating Profit
- —
- OPM %
- —
- Other Income
- 107
- Interest
- 115
- Depreciation
- 131
- 2,234
- Tax %
- 23.85%
- Net Profit
- 1,701
- 17
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2024
- 2,512
- 1,733
- Operating Profit
- —
- OPM %
- —
- Other Income
- 381
- Interest
- 96
- Depreciation
- 134
- 1,039
- Tax %
- 24.01%
- Net Profit
- 790
- 8
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2024
- 2,409
- 1,867
- Operating Profit
- —
- OPM %
- —
- Other Income
- 78
- Interest
- 97
- Depreciation
- 132
- 497
- Tax %
- 5.35%
- Net Profit
- 471
- 5
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2025
- 5,634
- 2,047
- Operating Profit
- —
- OPM %
- —
- Other Income
- 185
- Interest
- 155
- Depreciation
- 128
- 3,675
- Tax %
- 23.43%
- Net Profit
- 2,814
- 28
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2025
- 2,496
- 2,003
- Operating Profit
- —
- OPM %
- —
- Other Income
- 157
- Interest
- 138
- Depreciation
- 130
- 475
- Tax %
- 18.99%
- Net Profit
- 385
- 4
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Sep 2025
- 2,809
- 2,115
- Operating Profit
- —
- OPM %
- —
- Other Income
- 937
- Interest
- 114
- Depreciation
- 136
- 1,444
- Tax %
- 19.88%
- Net Profit
- 1,157
- 11
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Dec 2025
- 2,207
- 2,085
- Operating Profit
- —
- OPM %
- —
- Other Income
- 474
- Interest
- 116
- Depreciation
- 144
- 352
- Tax %
- 15.86%
- Net Profit
- 296
- 3
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Mar 2026
- 3,565
- 2,400
- Operating Profit
- —
- OPM %
- —
- Other Income
- 1,143
- Interest
- 116
- Depreciation
- 151
- 2,111
- Tax %
- 18.43%
- Net Profit
- 1,722
- 17
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 101
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Jun 2026
- 2,872
- 2,540
- Operating Profit
- —
- OPM %
- —
- Other Income
- 124
- Interest
- 103
- Depreciation
- 152
- 456
- Tax %
- 25.48%
- Net Profit
- 340
- 0
- Equity Capital
- 100
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 100
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3,231 | 5,810 | 6,037 | 6,347 | 7,780 | 7,837 | 8,732 | 10,819 | 15,116 | 11,484 | 11,453 | |
| 2,910 | 4,164 | 4,413 | 4,928 | 5,473 | 6,066 | 6,553 | 6,838 | 7,590 | 8,787 | 9,140 | |
| Operating Profit | 920 | 1,854 | 2,191 | 2,272 | 2,398 | 2,097 | 3,003 | 5,144 | 8,458 | 5,593 | — |
| OPM % | 28 | 32 | 36 | 36 | 31 | 27 | 34 | 48 | 56 | 49 | — |
| Other Income | 599 | 208 | 566 | 853 | 91 | 325 | 824 | 1,163 | 931 | 2,896 | 2,678 |
| Interest | 27 | 64 | 92 | 234 | 71 | 135 | 278 | 391 | 489 | 483 | 448 |
| Depreciation | 251 | 293 | 358 | 429 | 451 | 479 | 489 | 504 | 524 | 561 | 583 |
| 642 | 1,497 | 1,741 | 1,558 | 1,688 | 1,164 | 2,032 | 4,240 | 7,445 | 4,382 | 4,363 | |
| Tax % | -3 | 27 | 17 | 13 | 13 | 26 | 25 | 19 | 22 | 19 | 19 |
| Net Profit | 662 | 1,091 | 1,440 | 1,354 | 1,476 | 858 | 1,529 | 3,442 | 5,775 | 3,560 | 3,515 |
| EPS | 6 | 11 | 15 | 14 | 14 | 8 | 15 | 34 | 57 | 35 | — |
| Dividend Payout % | 50 | 33 | 25 | 26 | 24 | 30 | 40 | 9 | 19 | 3 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 6 | 11 | 14 | 13 | 14 | 8 | 15 | 34 | 57 | 35 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 6 | 11 | 14 | 13 | 14 | 8 | 15 | 34 | 57 | 35 | — |
Mar 2017
- 3,231
- 2,910
- Operating Profit
- 920
- OPM %
- 28
- Other Income
- 599
- Interest
- 27
- Depreciation
- 251
- 642
- Tax %
- -3
- Net Profit
- 662
- EPS
- 6
- Dividend Payout %
- 50
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 6
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 6
Mar 2018
- 5,810
- 4,164
- Operating Profit
- 1,854
- OPM %
- 32
- Other Income
- 208
- Interest
- 64
- Depreciation
- 293
- 1,497
- Tax %
- 27
- Net Profit
- 1,091
- EPS
- 11
- Dividend Payout %
- 33
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
Mar 2019
- 6,037
- 4,413
- Operating Profit
- 2,191
- OPM %
- 36
- Other Income
- 566
- Interest
- 92
- Depreciation
- 358
- 1,741
- Tax %
- 17
- Net Profit
- 1,440
- EPS
- 15
- Dividend Payout %
- 25
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
Mar 2020
- 6,347
- 4,928
- Operating Profit
- 2,272
- OPM %
- 36
- Other Income
- 853
- Interest
- 234
- Depreciation
- 429
- 1,558
- Tax %
- 13
- Net Profit
- 1,354
- EPS
- 14
- Dividend Payout %
- 26
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 13
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 13
Mar 2021
- 7,780
- 5,473
- Operating Profit
- 2,398
- OPM %
- 31
- Other Income
- 91
- Interest
- 71
- Depreciation
- 451
- 1,688
- Tax %
- 13
- Net Profit
- 1,476
- EPS
- 14
- Dividend Payout %
- 24
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 14
Mar 2022
- 7,837
- 6,066
- Operating Profit
- 2,097
- OPM %
- 27
- Other Income
- 325
- Interest
- 135
- Depreciation
- 479
- 1,164
- Tax %
- 26
- Net Profit
- 858
- EPS
- 8
- Dividend Payout %
- 30
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 8
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 8
Mar 2023
- 8,732
- 6,553
- Operating Profit
- 3,003
- OPM %
- 34
- Other Income
- 824
- Interest
- 278
- Depreciation
- 489
- 2,032
- Tax %
- 25
- Net Profit
- 1,529
- EPS
- 15
- Dividend Payout %
- 40
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 15
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 15
Mar 2024
- 10,819
- 6,838
- Operating Profit
- 5,144
- OPM %
- 48
- Other Income
- 1,163
- Interest
- 391
- Depreciation
- 504
- 4,240
- Tax %
- 19
- Net Profit
- 3,442
- EPS
- 34
- Dividend Payout %
- 9
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 34
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 34
Mar 2025
- 15,116
- 7,590
- Operating Profit
- 8,458
- OPM %
- 56
- Other Income
- 931
- Interest
- 489
- Depreciation
- 524
- 7,445
- Tax %
- 22
- Net Profit
- 5,775
- EPS
- 57
- Dividend Payout %
- 19
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 57
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 57
Mar 2026
- 11,484
- 8,787
- Operating Profit
- 5,593
- OPM %
- 49
- Other Income
- 2,896
- Interest
- 483
- Depreciation
- 561
- 4,382
- Tax %
- 19
- Net Profit
- 3,560
- EPS
- 35
- Dividend Payout %
- 3
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 35
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 35
TTM
- 11,453
- 9,140
- Operating Profit
- —
- OPM %
- —
- Other Income
- 2,678
- Interest
- 448
- Depreciation
- 583
- 4,363
- Tax %
- 19
- Net Profit
- 3,515
- EPS
- —
- Dividend Payout %
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
COMPOUNDED SALES GROWTH
- 10 Years:
- 5%
- 5 Years:
- 8%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 6%
- 5 Years:
- 19%
- 3 Years:
- 33%
STOCK PRICE CAGR
- 10 Years:
- 12%
- 5 Years:
- 16%
- 3 Years:
- 20%
- 1 Year:
- 14%
RETURN ON EQUITY
- 10 Years:
- 16%
- 5 Years:
- 18%
- 3 Years:
- 24%
- Last Year:
- 16%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - | - | - | - |
| Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 |
| 6,516 | 7,643 | 8,467 | 11,158 | 12,642 | 13,138 | 13,538 | 15,616 | 21,090 | 23,571 | |
| 1,654 | 1,344 | 1,442 | 1,529 | 2,696 | 2,031 | 969 | 618 | 3,020 | 2,673 | |
| Trade Payables | 996 | 803 | 701 | 863 | 1,126 | 1,065 | 1,043 | 1,112 | 1,232 | 1,472 |
| 2,564 | 3,356 | 4,362 | 4,504 | 3,520 | 3,589 | 7,434 | 10,050 | 11,596 | 11,194 | |
| Total Liabilities | 11,832 | 13,249 | 15,074 | 18,156 | 20,086 | 19,925 | 23,086 | 27,496 | 37,037 | 39,011 |
| ASSETS | - | - | - | - | - | - | - | - | - | - |
| 2,352 | 2,680 | 3,932 | 4,109 | 4,112 | 4,336 | 4,184 | 4,369 | 4,202 | 5,084 | |
| Capital Work in Progress | 678 | 659 | 675 | 553 | 570 | 384 | 739 | 627 | 1,188 | 621 |
| 3,924 | 3,618 | 4,195 | 6,404 | 6,471 | 5,118 | 4,879 | 7,283 | 11,492 | 11,478 | |
| 933 | 1,321 | 1,472 | 1,395 | 1,780 | 1,926 | 1,782 | 1,687 | 1,952 | 2,178 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4,740 | 8,162 | 8,495 | |
| Cash & Bank | 17 | 184 | 112 | 385 | 154 | 303 | 248 | 414 | 144 | 734 |
| 3,928 | 4,787 | 4,687 | 5,310 | 6,999 | 7,859 | 11,253 | 8,376 | 9,897 | 10,421 | |
| Total Assets | 11,832 | 13,249 | 15,074 | 18,156 | 20,086 | 19,925 | 23,086 | 27,496 | 37,037 | 39,011 |
| Total Debt | 2,940 | 2,872 | 3,583 | 3,697 | 3,916 | 2,663 | 4,822 | 6,174 | 8,339 | 7,431 |
| Net Working Capital | -874 | 761 | 1,456 | 1,343 | 1,211 | 2,810 | 4,368 | 5,370 | 7,463 | 10,659 |
| Contingent Liabilities | 2,304 | 2,589 | 3,158 | 3,750 | 1,560 | 1,828 | 366 | 1,313 | 1,447 | 5,569 |
| Book Value per Share | 64.63 | 75.64 | 83.68 | 109.96 | 124.46 | 129.30 | 134.78 | 156.23 | 210.64 | 235.31 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total Debt | 2,940 | 2,872 | 3,583 | 3,697 | 3,916 | 2,663 | 4,822 | 6,174 | 8,339 | 7,431 |
| Net Working Capital | -874 | 761 | 1,456 | 1,343 | 1,211 | 2,810 | 4,368 | 5,370 | 7,463 | 10,659 |
| Contingent Liabilities | 2,304 | 2,589 | 3,158 | 3,750 | 1,560 | 1,828 | 366 | 1,313 | 1,447 | 5,569 |
| Book Value per Share | 64.63 | 75.64 | 83.68 | 109.96 | 124.46 | 129.30 | 134.78 | 156.23 | 210.64 | 235.31 |
| Face Value | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Mar 2017
- Equity Capital
- 102
- 6,516
- 1,654
- Trade Payables
- 996
- 2,564
- Total Liabilities
- 11,832
- 2,352
- Capital Work in Progress
- 678
- 3,924
- 933
- 0
- Cash & Bank
- 17
- 3,928
- Total Assets
- 11,832
- Total Debt
- 2,940
- Net Working Capital
- -874
- Contingent Liabilities
- 2,304
- Book Value per Share
- 64.63
- Face Value
- 1.00
- Total Debt
- 2,940
- Net Working Capital
- -874
- Contingent Liabilities
- 2,304
- Book Value per Share
- 64.63
- Face Value
- 1.00
Mar 2018
- Equity Capital
- 102
- 7,643
- 1,344
- Trade Payables
- 803
- 3,356
- Total Liabilities
- 13,249
- 2,680
- Capital Work in Progress
- 659
- 3,618
- 1,321
- 0
- Cash & Bank
- 184
- 4,787
- Total Assets
- 13,249
- Total Debt
- 2,872
- Net Working Capital
- 761
- Contingent Liabilities
- 2,589
- Book Value per Share
- 75.64
- Face Value
- 1.00
- Total Debt
- 2,872
- Net Working Capital
- 761
- Contingent Liabilities
- 2,589
- Book Value per Share
- 75.64
- Face Value
- 1.00
Mar 2019
- Equity Capital
- 102
- 8,467
- 1,442
- Trade Payables
- 701
- 4,362
- Total Liabilities
- 15,074
- 3,932
- Capital Work in Progress
- 675
- 4,195
- 1,472
- 0
- Cash & Bank
- 112
- 4,687
- Total Assets
- 15,074
- Total Debt
- 3,583
- Net Working Capital
- 1,456
- Contingent Liabilities
- 3,158
- Book Value per Share
- 83.68
- Face Value
- 1.00
- Total Debt
- 3,583
- Net Working Capital
- 1,456
- Contingent Liabilities
- 3,158
- Book Value per Share
- 83.68
- Face Value
- 1.00
Mar 2020
- Equity Capital
- 102
- 11,158
- 1,529
- Trade Payables
- 863
- 4,504
- Total Liabilities
- 18,156
- 4,109
- Capital Work in Progress
- 553
- 6,404
- 1,395
- 0
- Cash & Bank
- 385
- 5,310
- Total Assets
- 18,156
- Total Debt
- 3,697
- Net Working Capital
- 1,343
- Contingent Liabilities
- 3,750
- Book Value per Share
- 109.96
- Face Value
- 1.00
- Total Debt
- 3,697
- Net Working Capital
- 1,343
- Contingent Liabilities
- 3,750
- Book Value per Share
- 109.96
- Face Value
- 1.00
Mar 2021
- Equity Capital
- 102
- 12,642
- 2,696
- Trade Payables
- 1,126
- 3,520
- Total Liabilities
- 20,086
- 4,112
- Capital Work in Progress
- 570
- 6,471
- 1,780
- 0
- Cash & Bank
- 154
- 6,999
- Total Assets
- 20,086
- Total Debt
- 3,916
- Net Working Capital
- 1,211
- Contingent Liabilities
- 1,560
- Book Value per Share
- 124.46
- Face Value
- 1.00
- Total Debt
- 3,916
- Net Working Capital
- 1,211
- Contingent Liabilities
- 1,560
- Book Value per Share
- 124.46
- Face Value
- 1.00
Mar 2022
- Equity Capital
- 102
- 13,138
- 2,031
- Trade Payables
- 1,065
- 3,589
- Total Liabilities
- 19,925
- 4,336
- Capital Work in Progress
- 384
- 5,118
- 1,926
- 0
- Cash & Bank
- 303
- 7,859
- Total Assets
- 19,925
- Total Debt
- 2,663
- Net Working Capital
- 2,810
- Contingent Liabilities
- 1,828
- Book Value per Share
- 129.30
- Face Value
- 1.00
- Total Debt
- 2,663
- Net Working Capital
- 2,810
- Contingent Liabilities
- 1,828
- Book Value per Share
- 129.30
- Face Value
- 1.00
Mar 2023
- Equity Capital
- 101
- 13,538
- 969
- Trade Payables
- 1,043
- 7,434
- Total Liabilities
- 23,086
- 4,184
- Capital Work in Progress
- 739
- 4,879
- 1,782
- 0
- Cash & Bank
- 248
- 11,253
- Total Assets
- 23,086
- Total Debt
- 4,822
- Net Working Capital
- 4,368
- Contingent Liabilities
- 366
- Book Value per Share
- 134.78
- Face Value
- 1.00
- Total Debt
- 4,822
- Net Working Capital
- 4,368
- Contingent Liabilities
- 366
- Book Value per Share
- 134.78
- Face Value
- 1.00
Mar 2024
- Equity Capital
- 101
- 15,616
- 618
- Trade Payables
- 1,112
- 10,050
- Total Liabilities
- 27,496
- 4,369
- Capital Work in Progress
- 627
- 7,283
- 1,687
- 4,740
- Cash & Bank
- 414
- 8,376
- Total Assets
- 27,496
- Total Debt
- 6,174
- Net Working Capital
- 5,370
- Contingent Liabilities
- 1,313
- Book Value per Share
- 156.23
- Face Value
- 1.00
- Total Debt
- 6,174
- Net Working Capital
- 5,370
- Contingent Liabilities
- 1,313
- Book Value per Share
- 156.23
- Face Value
- 1.00
Mar 2025
- Equity Capital
- 101
- 21,090
- 3,020
- Trade Payables
- 1,232
- 11,596
- Total Liabilities
- 37,037
- 4,202
- Capital Work in Progress
- 1,188
- 11,492
- 1,952
- 8,162
- Cash & Bank
- 144
- 9,897
- Total Assets
- 37,037
- Total Debt
- 8,339
- Net Working Capital
- 7,463
- Contingent Liabilities
- 1,447
- Book Value per Share
- 210.64
- Face Value
- 1.00
- Total Debt
- 8,339
- Net Working Capital
- 7,463
- Contingent Liabilities
- 1,447
- Book Value per Share
- 210.64
- Face Value
- 1.00
Mar 2026
- Equity Capital
- 101
- 23,571
- 2,673
- Trade Payables
- 1,472
- 11,194
- Total Liabilities
- 39,011
- 5,084
- Capital Work in Progress
- 621
- 11,478
- 2,178
- 8,495
- Cash & Bank
- 734
- 10,421
- Total Assets
- 39,011
- Total Debt
- 7,431
- Net Working Capital
- 10,659
- Contingent Liabilities
- 5,569
- Book Value per Share
- 235.31
- Face Value
- 1.00
- Total Debt
- 7,431
- Net Working Capital
- 10,659
- Contingent Liabilities
- 5,569
- Book Value per Share
- 235.31
- Face Value
- 1.00
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 867 | 288 | 581 | 1,181 | 2,227 | 1,272 | 1,078 | 2,000 | 3,114 | 2,234 | |
| Cash from Investing | -2,480 | 28 | -745 | 55 | -2,714 | 586 | -1,959 | -1,832 | -4,504 | 570 |
| Cash from Financing | 1,366 | -149 | 65 | -967 | 255 | -1,710 | 827 | -301 | 1,384 | -2,580 |
| -247 | 167 | -100 | 269 | -231 | 149 | -54 | -132 | -5 | 224 | |
| Free Cash Flow | 310 | -312 | -1,072 | 891 | 1,764 | 782 | 409 | 1,435 | 2,330 | 1,407 |
| OCF / Net Profit | 1.31 | 0.26 | 0.40 | 0.87 | 1.51 | 1.48 | 0.71 | 0.58 | 0.54 | 0.63 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 1,581 | 2,053 | 2,775 | 5,282 | 6,721 | 6,364 |
| OCF / Net Profit | 1.31 | 0.26 | 0.40 | 0.87 | 1.51 | 1.48 | 0.71 | 0.58 | 0.54 | 0.63 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 1,581 | 2,053 | 2,775 | 5,282 | 6,721 | 6,364 |
Mar 2017
- 867
- Cash from Investing
- -2,480
- Cash from Financing
- 1,366
- -247
- Free Cash Flow
- 310
- OCF / Net Profit
- 1.31
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.31
- Cumulative 5-Year FCF
- 0
Mar 2018
- 288
- Cash from Investing
- 28
- Cash from Financing
- -149
- 167
- Free Cash Flow
- -312
- OCF / Net Profit
- 0.26
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.26
- Cumulative 5-Year FCF
- 0
Mar 2019
- 581
- Cash from Investing
- -745
- Cash from Financing
- 65
- -100
- Free Cash Flow
- -1,072
- OCF / Net Profit
- 0.40
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.40
- Cumulative 5-Year FCF
- 0
Mar 2020
- 1,181
- Cash from Investing
- 55
- Cash from Financing
- -967
- 269
- Free Cash Flow
- 891
- OCF / Net Profit
- 0.87
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.87
- Cumulative 5-Year FCF
- 0
Mar 2021
- 2,227
- Cash from Investing
- -2,714
- Cash from Financing
- 255
- -231
- Free Cash Flow
- 1,764
- OCF / Net Profit
- 1.51
- Cumulative 5-Year FCF
- 1,581
- OCF / Net Profit
- 1.51
- Cumulative 5-Year FCF
- 1,581
Mar 2022
- 1,272
- Cash from Investing
- 586
- Cash from Financing
- -1,710
- 149
- Free Cash Flow
- 782
- OCF / Net Profit
- 1.48
- Cumulative 5-Year FCF
- 2,053
- OCF / Net Profit
- 1.48
- Cumulative 5-Year FCF
- 2,053
Mar 2023
- 1,078
- Cash from Investing
- -1,959
- Cash from Financing
- 827
- -54
- Free Cash Flow
- 409
- OCF / Net Profit
- 0.71
- Cumulative 5-Year FCF
- 2,775
- OCF / Net Profit
- 0.71
- Cumulative 5-Year FCF
- 2,775
Mar 2024
- 2,000
- Cash from Investing
- -1,832
- Cash from Financing
- -301
- -132
- Free Cash Flow
- 1,435
- OCF / Net Profit
- 0.58
- Cumulative 5-Year FCF
- 5,282
- OCF / Net Profit
- 0.58
- Cumulative 5-Year FCF
- 5,282
Mar 2025
- 3,114
- Cash from Investing
- -4,504
- Cash from Financing
- 1,384
- -5
- Free Cash Flow
- 2,330
- OCF / Net Profit
- 0.54
- Cumulative 5-Year FCF
- 6,721
- OCF / Net Profit
- 0.54
- Cumulative 5-Year FCF
- 6,721
Mar 2026
- 2,234
- Cash from Investing
- 570
- Cash from Financing
- -2,580
- 224
- Free Cash Flow
- 1,407
- OCF / Net Profit
- 0.63
- Cumulative 5-Year FCF
- 6,364
- OCF / Net Profit
- 0.63
- Cumulative 5-Year FCF
- 6,364
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | - | - | - | - | - | - | - | - | - | - |
| EPS (₹) | 6.46 | 10.65 | 14.06 | 13.22 | 14.42 | 8.38 | 15.11 | 34.21 | 57.40 | 35.39 |
| Book Value (₹) | 64.63 | 75.64 | 83.68 | 109.96 | 124.46 | 129.30 | 134.78 | 156.23 | 210.64 | 235.31 |
| Dividend per Share (₹) | 3.20 | 3.50 | 3.50 | 3.50 | 3.50 | 2.50 | 6.00 | 3.00 | 11.00 | 1.00 |
| Cash EPS (₹) | 8.91 | 13.51 | 17.56 | 17.41 | 18.82 | 13.05 | 19.94 | 39.22 | 62.61 | 40.96 |
| PROFITABILITY | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 28.10% | 31.84% | 36.29% | 35.80% | 30.72% | 26.72% | 34.43% | 36.77% | 49.75% | 23.39% |
| Net Margin % | 20.21% | 18.73% | 23.85% | 21.33% | 18.91% | 10.93% | 17.53% | 31.79% | 38.17% | 30.88% |
| ROE % | 10.27% | 15.19% | 17.65% | 13.65% | 12.30% | 6.60% | 11.38% | 23.45% | 31.29% | 15.87% |
| ROCE % | 7.85% | 15.47% | 16.10% | 13.22% | 11.13% | 7.98% | 13.45% | 22.95% | 30.86% | 16.05% |
| 6.16% | 8.70% | 10.17% | 8.15% | 7.72% | 4.29% | 7.11% | 13.61% | 17.90% | 9.36% | |
| EFFICIENCY | - | - | - | - | - | - | - | - | - | - |
| Debtor Days | 147 | 68 | 102 | 131 | 102 | 97 | 121 | 139 | 156 | 264 |
| Inventory Days | 89 | 71 | 84 | 82 | 74 | 86 | 78 | 58 | 44 | 65 |
| Payable Days | 411 | 235 | 177 | 172 | 182 | 162 | 148 | 152 | 174 | 169 |
| -176 | -96 | 9 | 42 | -6 | 21 | 50 | 46 | 25 | 160 | |
| FINANCIAL HEALTH | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity (x) | 0.44x | 0.37x | 0.42x | 0.33x | 0.31x | 0.20x | 0.35x | 0.39x | 0.39x | 0.31x |
| Interest Coverage (x) | 24.87x | 24.43x | 19.99x | 7.66x | 24.82x | 9.63x | 8.30x | 11.85x | 16.22x | 10.07x |
| 0.71x | 1.25x | 1.47x | 1.34x | 1.23x | 1.57x | 2.08x | 2.22x | 1.67x | 2.35x | |
| GROWTH | - | - | - | - | - | - | - | - | - | - |
| Revenue Growth % | -54.06% | 79.83% | 3.92% | 5.13% | 22.57% | 0.73% | 11.42% | 23.90% | 39.72% | -24.03% |
| Operating Profit Growth % | -66.56% | 101.54% | 18.17% | 3.71% | 5.52% | -12.56% | 43.21% | 71.29% | 64.43% | -33.87% |
| Net Profit Growth % | -67.51% | 64.80% | 31.99% | -5.99% | 9.06% | -41.88% | 78.25% | 125.05% | 67.80% | -38.36% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 126.39% | 67.80% | -38.36% | |
| VALUATION | - | - | - | - | - | - | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 29.38x | 15.43x | 24.62x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 6.43x | 4.20x | 3.70x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | 1.24% | 0.11% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 20.78x | 11.50x | 16.87x |
Mar 2017
- EPS (₹)
- 6.46
- Book Value (₹)
- 64.63
- Dividend per Share (₹)
- 3.20
- Cash EPS (₹)
- 8.91
- Operating Margin %
- 28.10%
- Net Margin %
- 20.21%
- ROE %
- 10.27%
- ROCE %
- 7.85%
- 6.16%
- Debtor Days
- 147
- Inventory Days
- 89
- Payable Days
- 411
- -176
- Debt to Equity (x)
- 0.44x
- Interest Coverage (x)
- 24.87x
- 0.71x
- Revenue Growth %
- -54.06%
- Operating Profit Growth %
- -66.56%
- Net Profit Growth %
- -67.51%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2018
- EPS (₹)
- 10.65
- Book Value (₹)
- 75.64
- Dividend per Share (₹)
- 3.50
- Cash EPS (₹)
- 13.51
- Operating Margin %
- 31.84%
- Net Margin %
- 18.73%
- ROE %
- 15.19%
- ROCE %
- 15.47%
- 8.70%
- Debtor Days
- 68
- Inventory Days
- 71
- Payable Days
- 235
- -96
- Debt to Equity (x)
- 0.37x
- Interest Coverage (x)
- 24.43x
- 1.25x
- Revenue Growth %
- 79.83%
- Operating Profit Growth %
- 101.54%
- Net Profit Growth %
- 64.80%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2019
- EPS (₹)
- 14.06
- Book Value (₹)
- 83.68
- Dividend per Share (₹)
- 3.50
- Cash EPS (₹)
- 17.56
- Operating Margin %
- 36.29%
- Net Margin %
- 23.85%
- ROE %
- 17.65%
- ROCE %
- 16.10%
- 10.17%
- Debtor Days
- 102
- Inventory Days
- 84
- Payable Days
- 177
- 9
- Debt to Equity (x)
- 0.42x
- Interest Coverage (x)
- 19.99x
- 1.47x
- Revenue Growth %
- 3.92%
- Operating Profit Growth %
- 18.17%
- Net Profit Growth %
- 31.99%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2020
- EPS (₹)
- 13.22
- Book Value (₹)
- 109.96
- Dividend per Share (₹)
- 3.50
- Cash EPS (₹)
- 17.41
- Operating Margin %
- 35.80%
- Net Margin %
- 21.33%
- ROE %
- 13.65%
- ROCE %
- 13.22%
- 8.15%
- Debtor Days
- 131
- Inventory Days
- 82
- Payable Days
- 172
- 42
- Debt to Equity (x)
- 0.33x
- Interest Coverage (x)
- 7.66x
- 1.34x
- Revenue Growth %
- 5.13%
- Operating Profit Growth %
- 3.71%
- Net Profit Growth %
- -5.99%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2021
- EPS (₹)
- 14.42
- Book Value (₹)
- 124.46
- Dividend per Share (₹)
- 3.50
- Cash EPS (₹)
- 18.82
- Operating Margin %
- 30.72%
- Net Margin %
- 18.91%
- ROE %
- 12.30%
- ROCE %
- 11.13%
- 7.72%
- Debtor Days
- 102
- Inventory Days
- 74
- Payable Days
- 182
- -6
- Debt to Equity (x)
- 0.31x
- Interest Coverage (x)
- 24.82x
- 1.23x
- Revenue Growth %
- 22.57%
- Operating Profit Growth %
- 5.52%
- Net Profit Growth %
- 9.06%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2022
- EPS (₹)
- 8.38
- Book Value (₹)
- 129.30
- Dividend per Share (₹)
- 2.50
- Cash EPS (₹)
- 13.05
- Operating Margin %
- 26.72%
- Net Margin %
- 10.93%
- ROE %
- 6.60%
- ROCE %
- 7.98%
- 4.29%
- Debtor Days
- 97
- Inventory Days
- 86
- Payable Days
- 162
- 21
- Debt to Equity (x)
- 0.20x
- Interest Coverage (x)
- 9.63x
- 1.57x
- Revenue Growth %
- 0.73%
- Operating Profit Growth %
- -12.56%
- Net Profit Growth %
- -41.88%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2023
- EPS (₹)
- 15.11
- Book Value (₹)
- 134.78
- Dividend per Share (₹)
- 6.00
- Cash EPS (₹)
- 19.94
- Operating Margin %
- 34.43%
- Net Margin %
- 17.53%
- ROE %
- 11.38%
- ROCE %
- 13.45%
- 7.11%
- Debtor Days
- 121
- Inventory Days
- 78
- Payable Days
- 148
- 50
- Debt to Equity (x)
- 0.35x
- Interest Coverage (x)
- 8.30x
- 2.08x
- Revenue Growth %
- 11.42%
- Operating Profit Growth %
- 43.21%
- Net Profit Growth %
- 78.25%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
Mar 2024
- EPS (₹)
- 34.21
- Book Value (₹)
- 156.23
- Dividend per Share (₹)
- 3.00
- Cash EPS (₹)
- 39.22
- Operating Margin %
- 36.77%
- Net Margin %
- 31.79%
- ROE %
- 23.45%
- ROCE %
- 22.95%
- 13.61%
- Debtor Days
- 139
- Inventory Days
- 58
- Payable Days
- 152
- 46
- Debt to Equity (x)
- 0.39x
- Interest Coverage (x)
- 11.85x
- 2.22x
- Revenue Growth %
- 23.90%
- Operating Profit Growth %
- 71.29%
- Net Profit Growth %
- 125.05%
- 126.39%
- P/E (x)
- 29.38x
- P/B (x)
- 6.43x
- Dividend Yield %
- 0.30%
- 20.78x
Mar 2025
- EPS (₹)
- 57.40
- Book Value (₹)
- 210.64
- Dividend per Share (₹)
- 11.00
- Cash EPS (₹)
- 62.61
- Operating Margin %
- 49.75%
- Net Margin %
- 38.17%
- ROE %
- 31.29%
- ROCE %
- 30.86%
- 17.90%
- Debtor Days
- 156
- Inventory Days
- 44
- Payable Days
- 174
- 25
- Debt to Equity (x)
- 0.39x
- Interest Coverage (x)
- 16.22x
- 1.67x
- Revenue Growth %
- 39.72%
- Operating Profit Growth %
- 64.43%
- Net Profit Growth %
- 67.80%
- 67.80%
- P/E (x)
- 15.43x
- P/B (x)
- 4.20x
- Dividend Yield %
- 1.24%
- 11.50x
Mar 2026
- EPS (₹)
- 35.39
- Book Value (₹)
- 235.31
- Dividend per Share (₹)
- 1.00
- Cash EPS (₹)
- 40.96
- Operating Margin %
- 23.39%
- Net Margin %
- 30.88%
- ROE %
- 15.87%
- ROCE %
- 16.05%
- 9.36%
- Debtor Days
- 264
- Inventory Days
- 65
- Payable Days
- 169
- 160
- Debt to Equity (x)
- 0.31x
- Interest Coverage (x)
- 10.07x
- 2.35x
- Revenue Growth %
- -24.03%
- Operating Profit Growth %
- -33.87%
- Net Profit Growth %
- -38.36%
- -38.36%
- P/E (x)
- 24.62x
- P/B (x)
- 3.70x
- Dividend Yield %
- 0.11%
- 16.87x
Documents
Announcements
- General Updates
2026-08-21 - Zydus Lifesciences Limited has informed the Exchange about General Updates
- Press Release
2026-08-21 - Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity".
Annual Reports
Credit Ratings
Nothing filed yet.
Concalls
Aug 2026
May 2026
Feb 2026